Unlocking new possibilities where current treatments fall short
At Recludix, we are committed to delivering new options for people with inflammatory diseases, developing new therapies designed with patients in mind and guided by the latest scientific advances. We understand that living with a chronic condition can be challenging, and we strive to provide better options, such as effective oral treatments, that address the needs of those we serve.
Clinical trial
We are conducting a carefully designed clinical trial to study a new oral therapy for inflammatory diseases, called REX-8756, that inhibits STAT6. This early phase study, called a Phase 1 trial, helps us understand how REX-8756 behaves in the body.
The study will involve approximately 100 healthy volunteers. It is “blinded,” which means neither participants nor researchers know who receives the drug or a placebo, which helps ensure unbiased results. Volunteers will be grouped into cohorts to receive different doses.
Starting in healthy volunteers allows us to carefully monitor safety, understand how REX-8756 is absorbed and processed in the body (pharmacokinetics), and see how it affects biological processes (pharmacodynamics) before determining a dose for people who have inflammatory diseases. Clinical testing is crucial to developing safe and effective treatments for the people who need them most.
Role of STAT6
STAT6 is a protein in the body that is involved in a pathway that can trigger inflammation, which is your body’s natural response to injury or infection. In some people with inflammatory diseases, this pathway becomes overactive, sending too many inflammatory signals, which can lead to diseases such as atopic dermatitis, asthma, and chronic obstructive pulmonary disease.
By inhibiting STAT6, we aim to reduce these overactive signals with REX-8756. Importantly, because STAT6 is a specific part of the inflammatory pathway, targeting it may allow for more precise treatment with fewer side effects compared to broader-acting drugs.